Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05114421
Title Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center

fallopian tube serous adenocarcinoma

peritoneal serous adenocarcinoma

ovarian serous carcinoma


Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.